BOSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- PathAI , a global leader in AI-powered pathology, today announced that the U.S. Food and Drug Administration (FDA) has qualified AIM-MASH AI Assist through ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic dysfunction-associated steatohepatitis (MASH) to help measure disease activity.
Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...
AIX-EN-PROVENCE, France--(BUSINESS WIRE)--E-Scopics, the France-based medical ultrasound company and creator of a unique software-based liver assessment tool, welcomed the announcement that Madrigal ...
The European Medicines Agency (EMA) offered a positive opinion last week on a new artificial intelligence (AI)–based tool that supports pathologists in diagnosing and assessing the severity of ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
The MarketWatch News Department was not involved in the creation of this content. BOSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback